Ionis Pharmaceuticals (NASDAQ: IONS) reported Q4 EPS of ($0.37), $0.55 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $152 million versus the consensus estimate of $158.8 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.